Showing 2551-2560 of 2891 results for "".
- CoolSculpting's New DTC Campaign is Brand's First to Feature Real Experiences with Treatmenthttps://modernaesthetics.com/news/coolsculptings-new-dtc-campaign-is-brands-first-to-feature-real-experiences-with-treatment/2473238/The newest direct-to-consumer campaign from CoolSculpting® launches this month and marks the first time the brand is featuring the real experiences of real people who have been treated with CoolSculpting® and CoolTone®. “CoolSculpting® Takes You Further&rdquo
- New Ophthalmologist-Created Eye Skincare Line Launcheshttps://modernaesthetics.com/news/new-ophthalmologist-created-eye-skincare-line-launches/2473236/Now available for pre-order, Daily Practice, the new eye care line by Ashley Brissette, MD, has launched with a hero product—Eye Revive. Having worked as an ophthalmologist for six years, New York City-based Dr. Brissette says she recognized a grow
- R2 Technologies Ships 100 GLACIAL Deviceshttps://modernaesthetics.com/news/r2-technologies-ships-100-glacial-devices/2473224/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Study: Skin of Color Patients Are Under-represented in Cosmetic Clinical Trialshttps://modernaesthetics.com/news/study-skin-of-color-patients-are-under-represented-in-cosmetic-clinical-trials/2473221/There’s a lack of ethnic/racial diversity in industry-sponsored aesthetic trials, according to new research in the April 2022 issue of Lasers in Surgery and Medicine. Researchers, led by Lisa Akintilo MD, MPH a current PGY-4 dermatology resident at New York
- Happy 20th Birthday Botox Cosmetic!https://modernaesthetics.com/news/happy-20th-birthday-botox-cosmetic/2473218/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Study: Sick Patients Get Cosmetic Surgery to Look Healthierhttps://modernaesthetics.com/news/study-sick-patients-get-cosmetic-surgery-to-look-healthier/2473216/Patients dealing with serious illnesses may want cosmetic procedures to make them look healthier, reports a small new Northwestern Medicine study. The patients believe cosmetic surgery may help them feel better in social situations with their friends, family or when they’re at work. &n
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Laser Surgery Lawsuits May be Less Likely with Physician Operatorshttps://modernaesthetics.com/news/laser-surgery-lawsuits-may-be-less-likely-with-physician-operators/2473208/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- The Beauty Health Company Introduces HydraFacial Syndeo Delivery Systemhttps://modernaesthetics.com/news/the-beauty-health-company-introduces-hydrafacial-syndeo-delivery-system/2473205/The Beauty Health Company is rolling out the HydraFacial Syndeo, a digital device that aims to enhance the consumer and provider experience. “As a category creator, we deliver beauty health experiences every day that re-invent our consumer’s relationship with their ski
- Revance Resubmits BLA for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-resubmits-bla-for-daxibotulinumtoxina/2473204/Revance Therapeutics, Inc. has resubmitted its Biologics License Application (BLA) to FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The submission is in response to the Complete Response Letter (CRL) issued by FDA in October 2021. The